Vaccines and immunotherapies against cancer: Injections with Gc-MAF a vitamin D binding protein work very effective (100% healing at a total of 40 patients after resp. 4 to 7 years) if destruction and protection against return of prostate cancer, breast cancer and colon cancer can be seen from three unconnected studies. Gc-MAF healing also plays role in AIDS, COPD and serious injuries. Gc-MAF seems decisive role to play in recovery of immune diseases and activation of own immune system. Study with Gc-Maf at Aidspatienten added.
10 november 2011: last weeks I had a correspondence with a orthomolecular doctor who told me that he with some colleagues were working with Gc-MAF on basis of nagalase testing. He would have me answers about the results of experiments on a Congress about Gc-MAF. I had previously sent him these two links demonstrating that there are still studies be done to Gc-MAF
19 June 2010:
Last time we get more and more questions about Gc-Maf. But I regret to say that we have no answer. However, Gc-Maf offered on internet but in our opinion this is not really reliable. Behind this website are the same people of DCA and yet we hear little more of there also. And nowhere is any proof that the Gc-Maf is offered on the internet is also the real Gc-Maf. And although these people very well know how you get on the internet to obtain publicity is the way they Gc-Maf offering my opinion dubious. They set up screens with studies and scientists and doctors but in e-mails to patients is nowhere indicated who the protocol of the study has set up, which doctors are involved and what happens with the data that patients possibly deliver. The patients must be signs that the providers may use their supplied data for promotion of their activities. Handy, of course, because that sells well. In addition, patients pay everything yourself what not usual in a study. And if it is true that these people are the real Gc-Maf they violate the patent that Dr. Yamamoto deliver on Gc-Maf injections and they are punishable.
It is a pity that so few of Dr. Yamamoto let yourself hear because Gc-Maf seems promising. Another study published last year Dr. Yamamoto with Aidspatienten and if it is true what the researchers claim this is really good news. The study from January 2009 with Aidspatienten and below the information about Gc-Maf studies in cancer etc. Down list of references of studies with Gc-Maf.
J Med Virol. 2009 Jan; 81 (1): 16-26.
Or HIV-infected patients with Gc protein immunotherapie-derived macrophage activating factor (GcMAF).
Ushijima N Yamamoto N, Koga Y,.
Division of Molecular Immunology and Socrates Institute for Therapeutic Immunology, Immunotherapie, Philadelphia, Pennsylvania 19126-3305, USA. nobutoyama@verizon.net
TranslateApiException: AppId is over the quota : ID=3641.V2_Json.Translate.1B661089TranslateApiException: AppId is over the quota : ID=3641.V2_Json.Translate.1B6610CFIt has been suggested that , in patients with advanced cancer, macrophages cannot be activated because cancer cells efficiently inactivate Gc-globulin. The cancer cells release an endoglycosidase (N-acetylgalactosaminidase) that inactivates Gc-MAF. Gc-MAF could restore the Replacing capability cancer cells or macrophages to remove (45) and could reverse the immunosuppression. The inactivation orNGc-MAF by a- -acetylgalactosaminidase is also thought to be involved in the etiology or immune-suppressed conditions, such as HIV infection (46) and systemic lupus erythematosus. Treatment of these patients with Gc-MAF to stimulate macrophages could offer a means of clearing immune complexes. These data provide evidence that Gc- MAF might have a spectrum of activities relevant for the treatment of cancer by improving immune surveillance.
The Gc-MAF, a vitamin D binding glyco-protein (a molecule with a glucose sugar and protein component) works 100% effective in the complete destruction of cancer cells within a year up to and the cancer comes back no longer even years later if this weekly is given whether or not after surgery at different forms of cancer. This is evident from a number of studies (see abstract below) performed by prostate cancer,respectively Japanese researchers atbreast cancer bowel cancerand. But also other studies indicate that according to the Japanese researchers as well as Gc-MAF works in all forms of cancer, even at bloedkanker species such as leukemia. The cost of this approach amounts averaging $ 150,--per injection and has on average say someone wekeljkse 35 inejcties. This, of course, still the cost of the doctors, hospital visit and making scans etc. But seems companies an affordable approach, especially when you consider that there is no bjkomende cost to fight infection and other side effects. And the quality of life of all participating patients bljikt excellent.
A weekly injection of Gc-MAF, it is a safe glyco-protein (a naturally produced molecule with a glucose component and a protein component) activates the human immune system and heals cancer final. This is evidenced by borstkankerpatientenstudies on isolated darmkankerpatienten including prostaatkankerpatienten, and. The complete remissions lasted at least 4 to 7 years depending on the duration. The effect of Gc-MAF shows 100%. No participating kankerpatient (40 total spread over 3 studies) to these studies got a return within or 4 to 7 years of his or her cancer. There were no side effects. The patients were further protected from reduced blood values and/or infections. Previous studies (all from 1993 publish Japanese researchers regularly about this approach) have already shown that this method is completely safe.
The abstract of the three studies referred to below and still some studies with Gc-MAF of Nobuto Yamamoto, director of the Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, Pennsylvania, which says in a recent American article "this is probably the most effective macrophage activating factor which is ever discovered". Would it still can be true and a cure for cancer within the possibilities go correctly?.
Immunotherapie for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.
Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, PA 19126-3305, USA.
Serum Gc protein (known as vitamin D (3)-binding protein) is the precursor for the principal macrophage-activating factor (MAF). The MAF precursor activity of serum Gc protein or prostate cancer patients was lost or reduced because Gc protein was deglycosylated by serum alpha-N-acetylgalactosaminidase (Nagalase) secreted from detecting pre-cancerous cells. Therefore, patients having deglycosylated Gc protein macrophages or prostate cancer cannot be activated, leading to immunosuppression. Stepwise treatment of purified Gc protein with immobilized beta-galactosidase and sialidase generated the most potent MAF (termed GcMAF) ever discovered, which produces no adverse effect in humans. Macrophages activated by GcMAF develop a considerable variation or receptors that recognize the abnormality in malignant cell surface and are highly tumoricidal. Sixteen nonanemic prostate cancer patients received weekly administration of 100 ng GcMAF or. As the MAF precursor activity increased, their serum Nagalase activity decreased. Because serum Nagalase activity is proportional to tumor burden, the entire time course analysis for GcMAF therapy was monitored by measuring the serum Nagalase activity. After 14 to 25 weekly administrations or GcMAF (100 ng/week), all 16 patients had very low serum Nagalase levels equivalent to those of healthy control values, indicating that these patients are tumour-free. No recurrence occurred for 7 years.
PMID: 18633461 [PubMed-in process]
PMCID: PMC2510818
Metastatic colorectal cancer with vitamin D-immunotherapie or binding protein-derived macrophage-activating factor, GcMAF.
Division of Cancer Immunology and Molecular Immunology, Socrates Institute for Therapeutic Immunology, 1040, 66th Ave, Philadelphia, PA 19126-3305, USA. nobutoyama@verizon.net
Serum vitamin D binding protein (Gc protein) is the precursor for the principal macrophage-activating factor (MAF). The MAF precursor activity of serum Gc protein or colorectal cancer patients was lost or reduced because Gc protein is deglycosylated by serum alpha-N-acetylgalactosaminidase (Nagalase) secreted from detecting pre-cancerous cells. Deglycosylated Gc protein cannot be converted to MAF, leading to immunosuppression. Stepwise treatment of purified Gc protein with immobilized beta-galactosidase and sialidase generated the most potent macrophage-activating factor (GcMAF) ever discovered, but it produces no side effect in humans. Macrophages treated with GcMAF (100 microg/ml) develop an enormous variation of receptors and are highly tumoricidal indiscriminately to a variety of cancers. Administration of 100 nanograms (ng)/human maximally activates systemic macrophages that can kill detecting pre-cancerous cells. Since the half-life of the activated macrophages is approximately 6 days, 100 ng GcMAF was administered weekly to colorectal cancer patients who had previously received nonanemic eight tumor resection but still carried significant amounts or metastatic tumor cells. As progressed, the MAF precursor GcMAF therapy activities or all patients increased and conversely their serum Nagalase activities decreased. Since serum Nagalase is proportional to tumor burden, serum Nagalase activity was used as a prognostic index for time course analysis GcMAF or therapy. After 32-50 or 100 ng GcMAF, all administrations weekly colorectal cancer patients exhibited healthy control levels of the serum Nagalase activity, indicating eradication or metastatic tumor cells. During 7 years after the completion of therapy, their serum Nagalase activity GcMAF did not increase, indicating no recurrence or cancer, which was also supported by the annual CT scans of these patients.
TranslateApiException: AppId is over the quota : ID=3737.V2_Json.Translate.1B65F607
1: Cancer Res. 1996 Jun 15; 56 (12): 2740-31.
Deglycosylation or serum vitamin D3-binding protein leads to immunosuppression in cancer patients.
Laboratory of Cancer Immunology and Molecular Biology, Albert Einstein Cancer Cener, Albert Einstein Medical Center, Philadelphia, Pennsylvania 19141, USA.
Serum vitamin D3-binding protein (Gc protein) can be converted by beta-galactosidase or B cells and T cells to a potent macrophage activating sialidase or factor, a protein with N-acetylgalactosamine as the remaining sugar moiety. Thus, Gc protein is the precursor of the macrophage activating factor (MAF). Treatment of Gc protein with immobilized beta-galactosidase and sialidase generates an extremely high titered MAF, Gc-MAF. When peripheral blood monocytes "/macrophages or 52 patients bearing various types of cancer were incubated with 100 pg/ml, GcMAF or the macrophages or monocytes"/all patients were efficiently activated. However, the MAF precursor activity or patient plasma Gc protein was found to be severely reduced in about 25% of this patient population. About 45% of the patients had moderately reduced MAF precursor activities. Loss of the precursor activity was found to be due to deglycosylation or plasma protein by alpha-N-acetylgalactosaminidase Gc detected in the patient's bloodstream. The source of the enzyme appeared to be detecting pre-cancerous cells. Radiation therapy decreased plasma alpha-N-acetylgalactosaminidase activity with concomitant increase of precursor activity. This implies that radiation therapy decreases the number of detecting pre-cancerous cells capable of secreting alpha-N-acetylgalactosaminidase. Both alpha-N-acetylgalactosaminidase activity and MAF precursor activity or Gc protein in patient bloodstream can serve as diagnostic and prognostic indices.
PMID: 8665521 [PubMed-indexed for MEDLINE]
TranslateApiException: AppId is over the quota : ID=3641.V2_Json.Translate.1B6614C9Immunotherapie or metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF).
Division of Cancer Immunology and Molecular Biology, Socrates Institute for Therapeutic Immunology, Philadelphia, PA 19126-3305, USA. nobutoyama@verizon.net
Serum vitamin D3-binding protein (Gc protein) is the precursor for the principal macrophage activating factor (MAF). The MAF precursor activity of serum Gc protein or breast cancer patients was lost or reduced because Gc protein was deglycosylated by serum alpha-N-acetylgalactosaminidase (Nagalase) secreted from detecting pre-cancerous cells. Patient serum Nagalase activity is proportional to tumor burden. The deglycosylated Gc protein cannot be converted to MAF, resulting in no macrophage activation and immunosuppression. Stepwise incubation or purified Gc protein with immobilized beta-galactosidase and sialidase generated probably the most potent macrophage activating factor (termed GcMAF) ever discovered, which produces no adverse effect in humans. Macrophages treated in vitro with GcMAF (100 pg/ml) are highly tumoricidal to mammary adenocarcinomas. Efficacy or GcMAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of GcMAF (100 ng). As therapy progresses, the MAF precursor activity GcMAF or patient Gc protein increased with a concomitant decrease in serum Nagalase. Because of proportionality or serum Nagalase activity to tumor burden, the time course progress or GcMAF therapy was assessed by serum Nagalase activity as a prognostic index. These patients had the initial Nagalase activities ranging from 2.32 to 6.28 nmole/min/mg protein. After about 16-22 administrations (approximately 3.5-5 months) or GcMAF, these patients had insignificantly low serum enzyme levels equivalent to healthy control enzyme levels, ranging from 0.38 to 0.63 nmole/min/mg protein, indicating eradication of the tumors. This therapeutic procedure resulted in no recurrence for more than 4 years. Copyright 2007 Wiley-Liss, Inc.
PMID: 17935130 [PubMed-indexed for MEDLINE]
- White P, Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab 2000; 11: 320-327.[CrossRef][ISI][Medline][Order article via Infotrieve]
- Lee WM, Galbraith RM. The extracellular actin-scavenger system and actin toxicity. N Engl J Med 1992; 326: 1335-1341.[ISI][Medline][Order article via Infotrieve]
- McLeod JF, Cooke NE.
The vitamin D-binding protein, albumin, multigene family fetoprotein-: detection of transcripts in multiple tissues. J Biol Chem 1989; 264: 21760-21769.[Free Abstract/Full Text] - DiMartino SJ, Kew RR. Initial characterization of the vitamin D binding protein (Gc-globulin) binding site on the neutrophil plasma membrane: evidence for a chondroitin sulfate proteoglycan. J Immunol 1999; 163: 2135-2142.[Free Abstract/Full Text]
- Haddad JG, Hu YZ, Kowalski MA, Lara more C, Ray K, Robzyk P, et al. Identification of the sterol-and actin-binding domains or plasma vitamin D binding protein. Biochemistry 1992; 31: 7174-7181.
